Vera Therapeutics, Inc. (Nasdaq: VERA) announced the appointment of Nancy Boman, M.D., Ph.D., as Chief Regulatory Officer, succeeding William Turner, who plans to retire and transition to a strategic advisor role in the third quarter of 2026.

Turner joined Vera Therapeutics and led the regulatory strategy that resulted in the accelerated approval of TRUTAKNA (atacicept-vymj), the company's therapy for IgA nephropathy (IgAN).

Boman brings more than 25 years of experience in regulatory affairs. She most recently served as Chief Regulatory Officer at Kyverna Therapeutics. Prior to that role, she held Chief Regulatory Officer positions at Adicet Bio, Encoded Therapeutics, and Novartis Gene Therapies. She has also held regulatory and clinical development leadership roles at Amgen, Genentech, and Alder. Boman holds a Ph.D. in biochemistry, an M.D., and a bachelor's degree in human physiology, all from the University of British Columbia.

"On behalf of the Board of Directors and everyone at Vera Therapeutics, I want to thank Bill for his exceptional leadership and for developing and executing the regulatory strategy resulting in the approval of TRUTAKNA," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.

"I am thrilled to join Vera Therapeutics at this pivotal moment and build upon the outstanding regulatory success the company has achieved under Bill's tenure," said Boman.

TRUTAKNA is indicated to reduce proteinuria in adults with primary IgAN at risk for disease progression. The approval is based on reduction of proteinuria under the accelerated approval pathway, and continued approval may depend on results from a confirmatory clinical trial.